6 days Ago By Defense World Staff
Legal & General Group Plc cut its stake in Evolus, Inc. ( NASDAQ:EOLS – Free Report ) by 5.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC).
The institutional investor owned 52,656 shares of the company’s stock after selling 2,783 shares during the period. Legal & General Group Plc owned approximately 0.08% of Evolus worth $581,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Dynamic Technology Lab Private Ltd boosted its stake in Evolus by 60.3% during the 4th quarter.
Dynamic Technology Lab Private Ltd now owns 18,886 shares of the company’s stock valued at $208,000 after purchasing an additional 7,103 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Evolus by 41.6% in the fourth quarter.
Wells Fargo & Company MN now owns 49,347 shares of the company’s stock valued at $545,000 after buying an additional 14,506 shares during the period. ExodusPoint Capital Management LP bought a new position in Evolus during the fourth quarter valued at about $149,000. Geode Capital Management LLC grew its holdings in Evolus by 0.
3% during the fourth quarter. Geode Capital Management LLC now owns 1,214,590 shares of the company’s stock worth $13,412,000 after acquiring an additional 3,969 shares during the period. Finally, Schroder Investment Management Group raised its position in Evolus by 2.
5% in the fourth quarter. Schroder Investment Management Group now owns 1,040,440 shares of the company’s stock worth $11,330,000 after acquiring an additional 25,480 shares in the last quarter. Institutional investors and hedge funds own 90.
69% of the company’s stock. Wall Street Analysts Forecast Growth A number of brokerages recently weighed in on EOLS. Needham & Company LLC restated a “buy” rating and set a $22.
00 target price on shares of Evolus in a report on Wednesday, April 9th. HC Wainwright reiterated a “buy” rating and set a $27.00 price objective on shares of Evolus in a research report on Thursday, April 10th.
BTIG Research started coverage on Evolus in a report on Thursday, April 17th. They issued a “buy” rating and a $21.00 target price on the stock.
Finally, Barclays upped their target price on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th.
Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Evolus currently has a consensus rating of “Buy” and an average price target of $23.75.
Insiders Place Their Bets In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of Evolus stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $60,147.
36. Following the completion of the sale, the chief marketing officer now owns 95,671 shares of the company’s stock, valued at $1,268,597.46.
This trade represents a 4.53 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink .
Also, insider Rui Avelar sold 27,904 shares of the company’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $370,007.
04. Following the completion of the transaction, the insider now directly owns 362,467 shares in the company, valued at $4,806,312.42.
This trade represents a 7.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here .
In the last ninety days, insiders sold 60,575 shares of company stock worth $794,369. 6.10% of the stock is currently owned by company insiders.
Evolus Stock Performance Shares of Evolus stock opened at $11.31 on Tuesday. The stock has a market cap of $719.
17 million, a PE ratio of -12.43 and a beta of 0.97.
Evolus, Inc. has a 12 month low of $8.67 and a 12 month high of $17.
82. The company has a quick ratio of 2.23, a current ratio of 2.
47 and a debt-to-equity ratio of 20.58. The business has a fifty day simple moving average of $12.
18 and a 200-day simple moving average of $12.86. About Evolus ( Free Report ) Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe.
The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. Read More Five stocks we like better than Evolus What is a support level? Best Defense Stocks in 2025..
. So Far Investing In Automotive Stocks Alphabet Rebounds After Strong Earnings and Buyback Announcement Do ETFs Pay Dividends? What You Need to Know Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? Want to see what other hedge funds are holding EOLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolus, Inc.
( NASDAQ:EOLS – Free Report ). Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter .
.
